Last updated: May 26, 2026
Binimetinib Suppliers: Who Manufactures It, What Builds the Supply Chain, and Where Procurement Risks Sit
Binimetinib supply is concentrated in a small set of global API and finished-dose manufacturers that can meet regulatory and scale requirements for the brand and authorized generics. Procurement decisions hinge on (1) whether your need is API versus finished capsules, (2) US NDA/ANDA-linked supply routes tracked through FDA, and (3) patent and regulatory lock-in that can restrict alternative sources.
What to buy matters. In practice, most “supplier” searches for binimetinib land in one of two lanes:
- API suppliers (binimetinib active pharmaceutical ingredient).
- Finished-dose suppliers (manufactured capsules shipped under brand/authorized labeling).
No complete, accurate supplier list can be produced here because the dataset required to map actual current manufacturing sites and named suppliers (FDA CDER Drug Registration and Listing, Orange Book linked ANDAs, DMF references, and procurement-grade supply contracts) is not provided in the prompt.
Which companies supply binimetinib API (active pharmaceutical ingredient)?
Direct answer: This cannot be stated without a source-backed mapping of binimetinib DMFs, site approvals, and current commercial supply registrations.
How binimetinib API sources are typically identified
- DMF holders and referenced manufacturers for binimetinib drug substance.
- FDA facility registrations linked to drug substance manufacture.
- Orange Book/ANDA linkages to identify which firms are producing at commercial scale for US marketing.
Who manufactures binimetinib capsules in the US market?
Direct answer: This cannot be stated without Orange Book-linked manufacturing and label/labeler data.
Key procurement distinctions
- Brand-labeled supply differs from:
- authorized generic routes,
- gap between US release and global packaging,
- contract manufacturing organizations (CMOs) that produce but do not “own” the NDA/ANDA.
What is the FDA regulatory status of binimetinib that affects supplier eligibility?
Direct answer: Cannot be completed without the specific NDA/market authorizations and corresponding FDA listings.
What supplier qualification usually depends on
- US marketing authorization holder and its quality agreements.
- Current Good Manufacturing Practice (cGMP) status of API and finished dose sites.
- Variations history and post-approval changes that can shift supply between sites.
What patents affect binimetinib supply, and do they block alternative manufacturers?
Direct answer: Cannot be mapped without the relevant patent estate and current litigation/settlement status tied to the exact marketed product and dosage forms.
Why patent status matters for suppliers
- Paragraph IV and settlement can delay entry of generic/authorized suppliers.
- Even if legal barriers ease, regulatory and data requirements still gate new API/finished-dose qualification.
Are there authorized generics or biosimilar-type substitutes for binimetinib?
Direct answer: Cannot be stated accurately without current FDA approvals and listings.
What to check in practice
- Orange Book for binimetinib drug products and their approval types.
- ANDA records showing the applicant and manufacturing responsibilities.
What generic entry risks exist for binimetinib (and when)?
Direct answer: Cannot be stated without the Orange Book list of patents, expiration dates, and any Paragraph IV activity.
What drives timing
- Patent expiration and regulatory exclusivity windows.
- Resolutions that cap generic entry dates or require specific labels.
What formulations of binimetinib are on the market, and do they change supplier choices?
Direct answer: Cannot be mapped without knowing the marketed dosage form(s) and their Orange Book entries.
Typical formulation-supply constraints
- Capsules vs tablets require different process lines.
- Fixed-dose strength can narrow which manufacturers can qualify quickly.
How does binimetinib compare with other MEK inhibitors on supplier availability?
Direct answer: Not computable here because supplier availability requires firm-level mapping across each product’s FDA-linked supply chain.
Procurement takeaway
Even within the same class, supplier ecosystems can differ due to:
- patent timelines,
- DMF accessibility and site qualification,
- packaging capacity and release testing capacity.
What manufacturing/IP barriers prevent new binimetinib suppliers from entering?
Direct answer: Cannot be listed precisely without the underlying patent estate and trade-secret protected process details tied to binimetinib’s manufacturing.
Typical barrier categories
- Proprietary polymorph/process controls for API.
- Formulation know-how and capsule filling parameters.
- Scale-up constraints for critical intermediates.
Key Takeaways
- A reliable binimetinib supplier map requires FDA-linked facility and regulatory data that is not present in the prompt.
- Procurement strategy should be split by API vs finished-dose supply lane.
- Patent and exclusivity status can restrict alternative manufacturing and commercial sourcing.
FAQs
- How do I find binimetinib API DMF holders in the US?
- What FDA databases list binimetinib manufacturing sites for drug substance and drug product?
- Do binimetinib capsules use contract manufacturing organizations (CMOs) and how do I identify them?
- What Orange Book fields determine whether a supplier can support an ANDA launch for binimetinib?
- How do I validate that a proposed binimetinib supplier can meet cGMP and release testing requirements?
References
No sources cited.
